Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Sort ascending Date Submission Received Date Recommendation Issued
Erbitux Cetuximab Cancelled
TBC filgrastim Prevention or treatment of neutropenia in various indications Cancelled
TBC filgrastim Cancelled
TBD Bevacizumab Cancelled
TBD Rituximab Cancelled
Translarna ataluren Cancelled
Atriance Nelarabine Cancelled
TBD Trastuzumab Cancelled
Truxima Rituximab Cancelled
TBC tirzepatide Diabetes mellitus, type 2 Cancelled